Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) reported its third-quarter 2021 earnings today after the closing bell. The revenue increased by 13% to $7.4 billion compared to the previous year. The net income was $2.5 billion or $2.05 per share compared to $360 million or $0.29 per share of the same quarter in the previous […]
Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) reported its third-quarter 2021 earnings today after the closing bell. The revenue increased by 13% to $7.4 billion compared to the previous year. The net income was $2.5 billion or $2.05 per share compared to $360 million or $0.29 per share of the same quarter in the previous […]
Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) reported its third-quarter 2021 earnings today after the closing bell.
The revenue increased by 13% to $7.4 billion compared to the previous year.
The net income was $2.5 billion or $2.05 per share compared to $360 million or $0.29 per share of the same quarter in the previous year.
The adjusted earnings per share were $2.65 compared to $2.11 of the previous year.
